BNTX BioNTech SE
Company Analysis
Latest News
BioNTech Halts Colorectal Cancer Vaccine Trial, Cites Survival Imbalance
BioNTech and partner Genentech terminated a Phase 2 trial for the mRNA-based cancer vaccine autogene cevumeran. The study focused on patients with high-risk...
🔴 BioNTech is trading 9.36% down today despite broader market gains
BioNTech is trading 9.36% down at $100.97, sharply underperforming the broader market, with no clear company-specific catalyst identified. - The FDA approved...
🔴 BioNTech is trading 4.5% down today as Nasdaq Composite falls 0.60%
BioNTech is trading down 4.5% at $111.33 amid a broader risk-off tone, with the Nasdaq Composite down 0.60%. - No new company-specific announcement explaining...
🟢 BioNTech is trading 5% up today on positive cancer-vaccine results from Moderna and Merck
BioNTech is trading 4.85% up now at $116.27, extending the strong August 19, 2026 rally; the move appears driven primarily by investor read-through from...
BioNTech to Reveal Lung Cancer Data, Highlighting Phase 3 Survival Results
BioNTech SE will present new clinical data from its lung cancer development program at the IASLC 2026 World Conference on Lung Cancer. The presentations...
🔴 BioNTech falls 4.9% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 BioNTech is trading 18% up today after positive melanoma-vaccine results from Moderna and Merck
BioNTech is trading 18% up now at $109.47 after positive Phase 3 melanoma-vaccine results from Moderna and Merck lifted mRNA and biotech sentiment. - Sector...
BioNTech and Pfizer Sued Over mRNA Patents, Risking Vaccine Injunctions
Arbutus and licensee Genevant Sciences filed patent infringement claims against BioNTech and Pfizer at the Unified Patent Court in The Hague. The lawsuit...
🟢 BioNTech is trading 14.29% up in pre-market with no clear company-specific catalyst identified
BioNTech is trading 14.29% up at $106.00 with no clear company-specific catalyst identified for August 19, 2026. - Its latest major event was the August 4...
BioNTech's second quarter revenue fell 60% to €105.6 million, driving a wider net loss
BioNTech reported second quarter revenue of €105.6 million, a sharp decrease from €260.8 million in the prior-year period, primarily due to declining COVID-19...
BioNTech's second quarter revenue fell to €105.6 million on lower vaccine demand, prompting a cut to its full-year 2026 guidance.
BioNTech reported second quarter revenues of €105.6 million, a significant decline from the prior year, driven by lower demand for its COVID-19 vaccine. The...
BioNTech SE Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
BioNTech is expected to report a Q2 2026 revenue of approximately $185.4 million and a consensus EPS of -$2.58, as the stock trades near $94.12 against a...
BioNTech and Pfizer Secure EU Approval for 2026-2027 COVID-19 Vaccine
The European Commission authorized BioNTech and Pfizer’s updated COVID-19 vaccine for the 2026-2027 season. This marketing authorization covers individuals...
🔴 BioNTech is trading 4.6% down today on macro uncertainty following new U.S. tariffs
BioNTech is trading 4.6% down at $85.22 in thin pre-market action, as the stock faces pressure from broader macro uncertainty following new U.S. tariffs on...
🔴 BioNTech is trading 4.4% down today with no clear company-specific catalyst
BioNTech is trading at $88.13 (-4.37%) in after-hours trading following an isolated selloff with no clear company-specific catalyst. • The decline follows a...
Sanofi Files New Patent Lawsuits Against Pfizer and BioNTech Over COVID-19 Vaccine Technology
Sanofi initiated new patent infringement lawsuits against Pfizer and its partner BioNTech, as well as Moderna. The lawsuits concern technology used in their...
🟢 BioNTech is trading 7% up today with no clear catalyst identified yet
BioNTech is trading at $96.51 (+7%) in after-hours trading with no clear catalyst identified yet, as the move likely reflects opportunistic buying following...
ARK Invest Sells $7.4 Million BioNTech Stake, Funds SpaceX
Cathie Wood’s ARK Invest sold 78,211 shares of BioNTech on July 8, 2026. The transaction was valued at approximately $7.4 million. ARK Invest reported the...
BioNTech Defeats mRNA Patent Claim, Court Rules Rival Patent Invalid
BioNTech and Pfizer secured a legal victory at the Unified Patent Court (UPC) in Munich. The court dismissed an infringement claim brought by Promosome...
BioNTech SE Q1 2026 Earnings Preview: What Analysts Expect on May 11, 2026
For the first quarter of 2026, analysts expect BioNTech to report a consensus revenue of approximately $207.42 million and an EPS loss of $2.03. With the stock...